DB:5P8

Stock Analysis Report

Executive Summary

Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics.


Snowflake Analysis

Flawless balance sheet and fair value.

Share Price & News

How has Five Prime Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 5P8's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

8.7%

5P8

8.1%

DE Biotechs

7.2%

DE Market


1 Year Return

-81.3%

5P8

-5.4%

DE Biotechs

-17.5%

DE Market

Return vs Industry: 5P8 underperformed the German Biotechs industry which returned -5.4% over the past year.

Return vs Market: 5P8 underperformed the German Market which returned -17.5% over the past year.


Shareholder returns

5P8IndustryMarket
7 Day8.7%8.1%7.2%
30 Day-49.6%-11.8%-22.3%
90 Day-44.1%-22.7%-26.1%
1 Year-81.3%-81.3%-5.2%-5.4%-14.9%-17.5%
3 Year-93.2%-93.2%17.6%16.3%-18.7%-25.7%
5 Year-87.8%-87.8%-5.1%-7.5%-17.8%-29.1%

Price Volatility Vs. Market

How volatile is Five Prime Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Five Prime Therapeutics undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 5P8 (€2.26) is trading below our estimate of fair value (€21.51)

Significantly Below Fair Value: 5P8 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 5P8 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 5P8 is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 5P8's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 5P8 is good value based on its PB Ratio (0.5x) compared to the DE Biotechs industry average (3.6x).


Next Steps

Future Growth

How is Five Prime Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

15.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 5P8 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 5P8 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 5P8 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 5P8's revenue (37.3% per year) is forecast to grow faster than the German market (4.2% per year).

High Growth Revenue: 5P8's revenue (37.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 5P8 is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Five Prime Therapeutics performed over the past 5 years?

-40.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 5P8 is currently unprofitable.

Growing Profit Margin: 5P8 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 5P8 is unprofitable, and losses have increased over the past 5 years at a rate of -40.6% per year.

Accelerating Growth: Unable to compare 5P8's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 5P8 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.7%).


Return on Equity

High ROE: 5P8 has a negative Return on Equity (-91.18%), as it is currently unprofitable.


Next Steps

Financial Health

How is Five Prime Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: 5P8's short term assets ($166.7M) exceed its short term liabilities ($23.0M).

Long Term Liabilities: 5P8's short term assets ($166.7M) exceed its long term liabilities ($50.6M).


Debt to Equity History and Analysis

Debt Level: 5P8 is debt free.

Reducing Debt: 5P8 has not had any debt for past 5 years.


Balance Sheet

Inventory Level: 5P8 has a high level of physical assets or inventory.

Debt Coverage by Assets: 5P8's debt is covered by short term assets (assets are 2.34637540586E+16x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 5P8 has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: 5P8 has sufficient cash runway for 2 years if free cash flow continues to reduce at historical rates of -32.9% each year.


Next Steps

Dividend

What is Five Prime Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 5P8's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 5P8's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 5P8's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 5P8's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 5P8's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.7yrs

Average management tenure


CEO

Bill Ringo (74yo)

0.50

Tenure

US$175,850

Compensation

Mr. William R. Ringo, Jr., also known as Bill, serves as Chief Executive Officer of Five Prime Therapeutics, Inc. since 2019 and was its Interim Chief Executive Officer since September 18, 2019 until 2019. ...


Leadership Team

NamePositionTenureCompensationOwnership
William Ringo
Chairman of the Board & CEO0.50yrUS$175.85k0.028% $21.0k
David Smith
Executive VP & CFO1.33yrsUS$2.43m0.18% $133.2k
Helen Collins
Executive VP & Chief Medical Officer3yrsUS$1.34m0.18% $136.6k
Francis Sarena
Chief Strategy Officer & Secretary9.25yrsUS$1.31m0.30% $220.7k
David White
Principal Accounting Officer1.08yrsno data0.12% $90.3k
Martin Forrest
Vice President of Investor Relations & Corporate Communicationsno datano datano data
Nallakkan Arvindan
Senior Vice President of Strategic Technology Operations2.08yrsno datano data

1.7yrs

Average Tenure

56yo

Average Age

Experienced Management: 5P8's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
William Ringo
Chairman of the Board & CEO0.50yrUS$175.85k0.028% $21.0k
Joseph Goldstein
Member of Scientific Advisory Boardno datano datano data
Daniel Von Hoff
Member of Scientific Advisory Boardno datano datano data
Peder Jensen
Independent Director8.67yrsUS$177.10kno data
Robert Lefkowitz
Member of Scientific Advisory Boardno datano datano data
Ronald Levy
Member of Scientific Advisory Boardno datano datano data
Franklin Berger
Independent Director9.5yrsUS$168.35k0.014% $10.5k
Drew Pardoll
Member of Scientific Advisory Boardno datano datano data
Arthur Weiss
Member of Scientific Advisory Boardno datano datano data
Garry Nicholson
Independent Director2.83yrsUS$167.52kno data

5.8yrs

Average Tenure

71yo

Average Age

Experienced Board: 5P8's board of directors are considered experienced (5.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.9%.


Top Shareholders

Company Information

Five Prime Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Five Prime Therapeutics, Inc.
  • Ticker: 5P8
  • Exchange: DB
  • Founded: 2001
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$82.322m
  • Listing Market Cap: US$74.246m
  • Shares outstanding: 35.33m
  • Website: https://www.fiveprime.com

Number of Employees


Location

  • Five Prime Therapeutics, Inc.
  • 111 Oyster Point Boulevard
  • South San Francisco
  • California
  • 94080
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
FPRXNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDSep 2013
5P8DB (Deutsche Boerse AG)YesCommon StockDEEURSep 2013
5P8BRSE (Berne Stock Exchange)YesCommon StockCHCHFSep 2013

Biography

Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company’s product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase 3 clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that is in Phase 1a/1b clinical trial that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein, which is in Phase 1a/1b clinical trial that enhances co-stimulation of T cells through CD28. Its product candidates also include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with Opdivo. The company’s BMS-986258, an anti-T cell immunoglobulin and mucin domain-3 antibody, which is in Phase 1/2 clinical trial as a single agent and in combination with Opdivo in patients with advanced malignant tumors. It has license and collaboration agreements with Bristol-Myers Squibb Company, GlaxoSmithKline LLC, INBRX 110 LP, UCB Pharma S.A., and Zai Lab (Shanghai) Co., Ltd.; and license agreements with Galaxy Biotech, LLC, BioWa, Inc. and Lonza Sales AG. The company was founded in 2001 and is headquartered in South San Francisco, California. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/27 23:58
End of Day Share Price2020/03/27 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.